Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06203652
Recruiting Observational

The Pathogenesis and Prognostic Factors of Lymphoma

NCT06203652 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Zhongshan Hospital
Phase
Observational
Started
2023-06-05
Last updated
2024-01-12

Condition(s) studied

LymphomaHodgkin LymphomaNon-hodgkin Lymphoma

Investigational drug(s) / intervention(s)

Real-world regimen

Real-world regimen: The final personalized management strategy is determined based on current conventional treatment options, physician and patient preferences.The following protocols: chemotherapy, immunochemotherapy,Anti-cd20 monoclonal antibody, BTKi and so on

Study summary

The aim of this study is to describe the clinical and genetic characteristics of Chinese lymphoma patients, and to explore the relationship between those characteristics and phatogenesis.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with pathological diagnosis of lymphoma (including Hodgkin lymphoma and non-Hodgkin lyphoma, eg. THRLBCL, DLBCL, MZL, CLL/SLL...) from 2007 to 2027. * Patients with complete diagnostic, treatment and follow-up records. * Fully comprehension and signature of the informed consent form (ICF) for participation. Exclusion Criteria: * Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period. * Severe mental illness. * Patients deemed unsuitable for inclusion by the investigator.

Primary outcome measure(s)

  • OS — Baseline up to data cut-off (Up to approximately 20 years)
    Overall survival (OS) refers to the time from receiving the first dose to death from any cause

Trial sites (1)

FacilityCityRegionStatus
Zhongshan Hospital，Fudan University Shanghai Shanghai Municipality Recruiting

More Shanghai Zhongshan Hospital trials in China

A Prospective Multicenter Clinical Study： IntracOronary neaR-Infrared Spectroscopy and OptIcal Coherence Tomography for Evaluating Coronary vulNerable Plaque in Patients With diabeTes Recruiting
Trends and Risk Factors of Adverse Cardiovascular and Cerebrovascular Events After Primary PCI Recruiting
Improve the Strategies of Endoscopic and Interventional Treatment of Gastroesophageal Hemorrhage in Portal Hypertension Recruiting
In Vivo CAR-T for Refractory Graves' Disease Recruiting
The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial Recruiting

Other trials for the same condition

Optimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism Lymphoma Recruiting
A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas Recruiting
Prognostic Model of Elderly Hodgkin Lymphoma in China Active, not recruiting
CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma Recruiting
Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06203652 on ClinicalTrials.gov ↗ ← All trials in China